A large 2025 pooled analysis published in JAMA Cardiology has added statistical weight to something clinicians have observed for years: the menopause transition is associated with a sharp, age-independent inflection in atherogenic lipid markers - and standard screening intervals are too long to catch it before it compounds.
What the analysis found
Drawing on longitudinal cohort data from over 4,000 women across multiple study sites, the analysis tracked ApoB, LDL-C, and triglycerides across the STRAW+10 reproductive aging stages. The headline finding: ApoB increased more steeply in the late perimenopause and early postmenopause stages than at any other point in the reproductive lifespan - independently of age, BMI, and dietary change.
The mean ApoB increase across the transition was approximately 8–10 mg/dL - equivalent to a decade of typical age-related drift compressed into two to three years. LDL-C showed a similar but smaller signal. The implication: a woman screened at 40 and again at 45 may appear stable, while her lipid trajectory has inflected sharply in the interval.
Clinical implication
Current ACC/AHA guidelines recommend lipid screening every 4–6 years for adults without established cardiovascular disease. For women in their early-to-mid 40s approaching the transition, this interval may be insufficient to capture the inflection point before atherosclerosis begins accumulating.
The authors stop short of recommending a new guideline - the evidence is observational, not interventional - but call for prospective studies testing annual ApoB monitoring during the perimenopause transition as a strategy for earlier cardiovascular risk identification.
Context from earlier research
This finding is consistent with El Khoudary et al.'s 2020 Circulation review, which documented LDL, ApoB, and triglyceride increases during the menopause transition across the Study of Women's Health Across the Nation (SWAN) cohort. The new analysis strengthens the signal with a larger pooled sample and more granular staging.
EllaDx includes ApoB in all metabolic and cardiovascular panels. If you are 40–50 and haven't retested your lipid markers in the past 12–18 months, this evidence supports doing so - particularly if your last panel was pre-transition.